Annette Beatrix Brühl1, Lutz Jäncke, Uwe Herwig. 1. Clinic for General and Social Psychiatry, Psychiatric University Hospital Zürich, Militärstrasse 8, Zürich, Switzerland. annette.bruehl@puk.zh.ch
Abstract
RATIONALE: Most widely used antidepressant drugs affect the serotonergic and noradrenergic pathways. However, there are currently no neurobiological criteria for selecting between these targets and predicting the treatment response in individual depressed patients. OBJECTIVES: The current study is aimed at differentiating brain regions known to be pathophysiologically and functionally involved in depression-related emotion processing with respect to their susceptibility to serotonergic and noradrenergic modulation. METHODS: In a single-blind pseudo-randomized crossover study, 16 healthy subjects (out of 21 enrolled) were included in analysis after ingesting a single dose of citalopram (a selective serotonin-reuptake inhibitor, 40 mg), reboxetine (a selective noradrenaline-reuptake inhibitor, 8 mg), or placebo at three time points prior to functional magnetic resonance imaging (fMRI). During fMRI, subjects anticipated and subsequently viewed emotional pictures. Effects of serotonergic and noradrenergic modulation versus placebo on brain activity during the perception of negative pictures were analyzed with a repeated measures ANOVA in the whole brain and in specific regions of interest relevant to depression. RESULTS: Noradrenergic modulation by reboxetine increased brain activity in the thalamus, right dorsolateral prefrontal cortex and occipital regions during the perception of negative emotional stimuli. Citalopram primarily affected the ventrolateral prefrontal cortical regions. CONCLUSION: The brain regions involved in the processing of negative emotional stimuli were differentially modulated by selective noradrenergic and serotonergic drugs: thalamic activity was increased by reboxetine, whereas citalopram primarily affected ventrolateral prefrontal regions. Thus, dysfunction in these regions, which could be identified in depressed patients, may predict treatment responses to either noradrenergic or serotonergic antidepressants.
RCT Entities:
RATIONALE: Most widely used antidepressant drugs affect the serotonergic and noradrenergic pathways. However, there are currently no neurobiological criteria for selecting between these targets and predicting the treatment response in individual depressedpatients. OBJECTIVES: The current study is aimed at differentiating brain regions known to be pathophysiologically and functionally involved in depression-related emotion processing with respect to their susceptibility to serotonergic and noradrenergic modulation. METHODS: In a single-blind pseudo-randomized crossover study, 16 healthy subjects (out of 21 enrolled) were included in analysis after ingesting a single dose of citalopram (a selective serotonin-reuptake inhibitor, 40 mg), reboxetine (a selective noradrenaline-reuptake inhibitor, 8 mg), or placebo at three time points prior to functional magnetic resonance imaging (fMRI). During fMRI, subjects anticipated and subsequently viewed emotional pictures. Effects of serotonergic and noradrenergic modulation versus placebo on brain activity during the perception of negative pictures were analyzed with a repeated measures ANOVA in the whole brain and in specific regions of interest relevant to depression. RESULTS: Noradrenergic modulation by reboxetine increased brain activity in the thalamus, right dorsolateral prefrontal cortex and occipital regions during the perception of negative emotional stimuli. Citalopram primarily affected the ventrolateral prefrontal cortical regions. CONCLUSION: The brain regions involved in the processing of negative emotional stimuli were differentially modulated by selective noradrenergic and serotonergic drugs: thalamic activity was increased by reboxetine, whereas citalopram primarily affected ventrolateral prefrontal regions. Thus, dysfunction in these regions, which could be identified in depressedpatients, may predict treatment responses to either noradrenergic or serotonergic antidepressants.
Authors: Eileen Daly; Quinton Deeley; Brian Hallahan; Michael Craig; Michael Brammer; Melissa Lamar; Anthony Cleare; Vincent Giampietro; Christine Ecker; Lisa Page; Fiona Toal; Mary L Phillips; Simon Surguladze; Declan G M Murphy Journal: Psychopharmacology (Berl) Date: 2010-04-28 Impact factor: 4.530
Authors: Thomas Frodl; Johanna Scheuerecker; Veronika Schoepf; Jennifer Linn; Nikolaos Koutsouleris; Arun L W Bokde; Harald Hampel; Hans-Jürgen Möller; Hartmut Brückmann; Martin Wiesmann; Eva Meisenzahl Journal: J Clin Psychiatry Date: 2010-09-21 Impact factor: 4.384
Authors: Gerard E Bruder; James P Sedoruk; Jonathan W Stewart; Patrick J McGrath; Frederic M Quitkin; Craig E Tenke Journal: Biol Psychiatry Date: 2007-12-03 Impact factor: 13.382
Authors: John T Little; Terence A Ketter; Tim A Kimbrell; Robert T Dunn; Brenda E Benson; Mark W Willis; David A Luckenbaugh; Robert M Post Journal: Biol Psychiatry Date: 2005-02-01 Impact factor: 13.382
Authors: Marleen Wingen; Kim P C Kuypers; Vincent van de Ven; Elia Formisano; Johannes G Ramaekers Journal: Hum Psychopharmacol Date: 2008-04 Impact factor: 1.672
Authors: J Horácek; L Závesická; J Tintera; C Dockery; V Platilová; M Kopecek; F Spaniel; V Bubeníková; C Höschl Journal: Physiol Res Date: 2005 Impact factor: 1.881
Authors: Elif Tunc-Ozcan; Sarah M Brooker; Jacqueline A Bonds; Yung-Hsu Tsai; Radhika Rawat; Tammy L McGuire; Chian-Yu Peng; John A Kessler Journal: Cell Mol Life Sci Date: 2021-12-22 Impact factor: 9.207
Authors: Tim Outhred; Pritha Das; Kim L Felmingham; Richard A Bryant; Pradeep J Nathan; Gin S Malhi; Andrew H Kemp Journal: J Psychiatry Neurosci Date: 2014-07 Impact factor: 6.186
Authors: C T Cerqueira; J R Sato; J R C de Almeida; E Amaro; C C Leite; C Gorenstein; V Gentil; G F Busatto Journal: Transl Psychiatry Date: 2014-07-01 Impact factor: 6.222